Expression and Purification of Functional Human Vascular Endothelial Growth Factor-\(\text{A}_{121}\); the Most Important Angiogenesis Factor

Fatemeh Kazemi-Lomedasht\(^1\), Mahdi Behdani\(^1*\), Kamran Pooshang Bagheri\(^1\), Mahdi Habibi Anbouhi\(^2\), Mohsen Abolhassani\(^3\), Hossein Khanahmad\(^4\), Delavar Shabazzadeh\(^5\), Hasan Mirzahoseini\(^1\)

\(^1\) Biotechnology Research Center, Venom & Biotherapeutics Molecules Lab., Pasteur Institute of Iran, Tehran, Iran.  
\(^2\) National Cell Bank of Iran, Pasteur Institute of Iran, Tehran, Iran.  
\(^3\) Department of Immunology, Hybridoma Lab, Pasteur Institute of Iran, Tehran, Iran.

Abstract

**Purpose:** Angiogenesis or formation of new blood vessels is an essential process for tumor growth, invasion and metastasis. Vascular Endothelial Growth Factor (VEGF) and its receptors play an important role in angiogenesis-dependent tumors. VEGF-A is the most important factor in angiogenesis process. Human VEGF-A gene consists of eight exons that undergoes alternative exon splicing and produce five different proteins consisting of \(121\), \(145\), \(165\), \(189\) and \(206\) amino acids (named VEGF\(_{121}\), VEGF\(_{145}\), VEGF\(_{165}\), VEGF\(_{189}\) and VEGF\(_{206}\)).

**Methods:** In this study, VEGF\(_{121}\) gene synthesized and cloned into the pET-26b plasmid. The recombinant plasmid was transferred into appropriate expression strain of BL-21. Expression of VEGF\(_{121}\) induced by IPTG (Isopropyl \(\beta\)-D-1-thiogalactopyranoside) and confirmed by SDS-PAGE and Western-Blotting. Recombinant VEGF\(_{121}\) was purified by nickel affinity chromatography. HUVECs (Human Umbilical Vein Endothelia Cells) cells were isolated from umbilical vein and the effect of VEGF\(_{121}\) on tube formation of endothelial cells was investigated.

**Results:** SDS-PAGE and Western-Blotting results verified the purification of VEGF\(_{121}\). The final yield of recombinant protein was about 5mg per liter. Endothelial cell tube formation assay results showed that VEGF\(_{121}\) leads to tube formation of endothelial cell on matrix and induces angiogenesis in vitro.

**Conclusion:** Recombinant VEGF\(_{121}\) is important factor in tube formation of endothelial cell, so it could be used in different cancer researches and angiogenesis assay.

Introduction

Angiogenesis is a fundamental process which is tightly regulated and resulted in the formation of new blood vessels from the previous vessel. This process is an essential component in the growth of normal cells and tissues during embryonic development, reproductive cycle and wound healing. Angiogenesis also play a critical role in pathological conditions, such as; age related macular degeneration (AMD), rheumatoid arthritis (RA) and diabetes retinopathies.\(^1\)-\(^3\) Vascular Endothelial Growth Factor is the most important regulators of angiogenesis.\(^6\)-\(^7\) VEGF family consist of seven secretory glycoproteins named, VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E, VEGF-F and Placental Growth Factor (PIGF).\(^8\)-\(^9\) The biological action of vascular endothelial growth factors has on its target cells through interactions with receptor tyrosine kinase in the plasma membrane cells conduct.\(^10\) The binding of VEGF and its receptor cause receptor dimmer and autophosphorylation.\(^11\) Ultimately these events led to the growth of endothelial cell and angiogenesis. VEGF ligands induce their effects by binding to three tyrosine kinase receptors -1,-2 and -3 (VEGFR-1, 2, 3).\(^12\) VEGF-A is the Main factor in the angiogenesis and acts its effect through the activation of VEGFR-1 and VEGFR-2. The human VEGF-A gene consists of eight exons which undergoes alternative exon splicing and results five different proteins consisting of \(121\), \(145\), \(165\), \(189\) and \(206\) amino acids (named VEGF\(_{121}\), VEGF\(_{145}\), VEGF\(_{165}\), VEGF\(_{189}\), VEGF\(_{206}\)). Exons 1-5 are conserved in all isoforms and alternative splicing occur in exon 6 and 7. VEGF\(_{165}\) lacks the exon 6 and is moderately diffusible but VEGF\(_{121}\) lacks both exon 6 and 7 and is highly diffusible.\(^13\) VEGF\(_{121}\) and VEGF\(_{165}\) are the most physiologically relative isoforms.\(^14\) VEGF\(_{121}\) has a disulfide band and form homodimer with molecular weight of \(28kDa\). The molecular weight of its monomer form is 16 \(kDa\).\(^15\) To evaluate the effect of angiogenic inducers and inhibitors some in vitro models have been developed including endothelial tube assay, proliferation assay and scratch assay.\(^16\)-\(^22\) In endothelial tube assay, endothelial

*Corresponding author: Mahdi Behdani, Tel/Fax: (+98) 21 66480780, Email: Behdani73042@yahoo.com

\(^{22}\) 2014 The Authors. This is an Open Access article distributed under the terms of the Creative Commons Attribution (CC BY), which permits unrestricted use, distribution, and reproduction in any medium, as long as the original authors and source are cited. No permission is required from the authors or the publishers.
cells interact with a matrix which helps cells to attached, aligned and form tube-like structure without cell proliferation. Because cell tube formation of endothelial cells on basement membrane mimics many steps of the angiogenesis, it has been widely used as a screen for angiogenic and anti-angiogenic factors. Since the most important regulators of angiogenesis are vascular endothelial growth factors so to achieve the goal, these factors should be considered. The goal of this study was cloning, expression and purification of recombinant human VEGF, as well as assessment of its in vitro biological activity by endothelial tube formation and proliferation assays.

Materials and Methods

Gene construction of pET26-VEGF

The gene sequence corresponding to the human VEGF adapted to the genome of E.coli BL-21(DE3) and synthesized by Biomatik Co. (Canada). The synthesized gene was amplified by specific primers which anchored with NdeI and XhoI restriction sites (Table 1). pET-26b plasmid and amplified VEGF gene were digested with the restriction enzymes and ligated overnight at 16°C. The construct was transformed into E.coli BL-21(DE3) competent cells and confirmed by colony-PCR with T7 promoter and T7 terminator primers. The integrity of final construct (pET26-VEGF) was confirmed by double digestion and DNA sequencing.

### Table 1. Specific primers of VEGF with restriction sites (in bold and underlined)

<table>
<thead>
<tr>
<th>Primer name</th>
<th>Sequence 5’→3’</th>
<th>Length (bp)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Forward primer</td>
<td>ACGCATATGGGCACCATGGCGAGAG (NdeI site)</td>
<td>26</td>
</tr>
<tr>
<td>Reverse primer</td>
<td>ACGCTCGAGCCGCTCCTGGCTTG (XhoI site)</td>
<td>22</td>
</tr>
</tbody>
</table>

### Recombinant Expression of VEGF

One colony of BL-21(DE3) E.coli include confirmed construct inoculated into LB Broth medium. The bacteria in log phase (OD600nm = 0.5-0.9) was induced with 1 mM of IPTG and incubated for 12-14h at 37°C, 180rpm. Expression was confirmed with SDS-PAGE and western blotting. SDS-PAGE was performed with 15% polyacrylamide gel. For western blotting, the protein bands were transferred onto nitrocellulose paper, and was blocked with 4% skim milk for 2 hours, then incubated with first antibody (human anti-VEGF) solution (1/4000) for 1 hour and second antibody (anti-human HRP conjugated) for another 1 hour. The recombinant protein was detected by ECL development (Electro Chemo Luminescence, GE, Healthcare).

### Recombinant VEGF Purification

After overnight induction with IPTG, the bacterial pellet was resuspended in binding buffer (Imidazole 30mM, NaCl 500mM, Tris 50mM and Urea 8M) and incubated for 1 hour in cold room. After that, the suspension was ultrasonicated for 15 second and 15 times (0.5 cycle and amplitude of 1). The remaining cells debris were precipitate by centrifugation at 8,000rpm for 30min. Protein extract from the bacteria were loaded on nickel affinity column (QIAGEN, Germany) according to the method proposed by the company producers. After washing with washing buffer (Imidazole 60mM, NaCl 500mM, Tris 50mM and Urea 4M), the recombinant protein was eluted with Elution buffer (Phosphate Buffered Saline (PBS) with Imidazole 500mM). For refolding, the recombinant protein was dialyzed against PBS. Finally, the purification process was confirmed by 15% SDS-PAGE (Reduced condition) and Western Blotting. The final yield was determined by Bradford assay. The purified VEGF lyophilized in a freeze dryer system (Christ, 2 alpha - Germany) at -55°C and stored at -20°C for further use.

Isolation of HUVEC cells from umbilical vein

Human umbilical cord collected from Babak hospital, (Tehran, Iran) and transferred to laboratory in transfer buffer (PBS, 0.2% glucose, 0.5M EDTA, 100U/ml penicillin and 100µg/ml streptomycin). The isolation of HUVEC cells from embryonic umbilical vein was done according to Bruno Baudin protocol. Briefly, umbilical vein was washed with DPBS (D-glucose and PBS) solution. Collagenase type 1 solution (Sigma) was used for isolation of HUVEC cells. After 30 min incubation at 37°C, the cells collected and centrifuged at 2000rpm for 5 minutes. Supernatant was removed and cells pellet resuspended in M200 ( Gibco, Invitrogen) culture medium supplemented with 10% heat inactivated FBS (Fetal Bovine Serum) (Gibco, Invitrogen), and low Endothelial Cell Growth Supplement (ECGS, Gibco, Invitrogen), penicillin G 100U/ml (Sigma) and streptomycin 100µg/ml (Sigma), and transferred into 25 cm² culture flask and incubated at 37°C with humidified air containing 5% CO₂. After 3-7 days, cells confluency was checked. The cells detached from culture flask with trypsin-EDTA (Sigma) and used for next experiments.

### Cell proliferation assay

About 2×10⁴ HUVEC cells seeded in 24-well plate with 1 ml of M200 medium supplemented with 2% FBS. Next day, the cells were washed with PBS and incubated in serum starvation medium (M200 with 0.1% FBS). After 24 h incubation at 37°C and 5% CO₂, different concentrations of VEGF(10, 50, 75 and 100 ng/ml) and standard commercial VEGF from R&D system (10, 50, 75 and 100 ng/ml) were added to the wells and incubated for an additional 24 h. Finally, the cells trypsinized and counted against control well.

### Endothelial tube formation assay

Geltrex™ LDEV-Free Reduced Growth Factor Basement Membrane (Gibco, Invitrogen) solution was thawed on ice...
and 50µl aliquots were transferred into a 96-well plate and incubated at 37°C for 30 minutes to solidify. Hundred microliters of M200 medium containing about 10^4 HUVEC cells (at least from 2nd passage, but not more than 6 passages) were added to each well on Geltrex™. The cells were treated with 0.1% FBS and VEGF_121 (75ng/ml). The assay was done in triplicate and plate incubated at 37°C for 30 minutes to solidify. Hundred microliters of M200 medium containing about 10^4 HUVEC cells (at least from 2nd passage, but not more than 6 passages) were added to each well on Geltrex™. The cells were treated with 0.1% FBS and VEGF_121 (75ng/ml). The assay was done in triplicate and plate incubated at 37°C with 5% CO₂. After 4, 6 and 16 hours of incubation, the cells and tube formation conditions observed under invert microscope (INV100-FL, BEL-Italy).

**Results**

**Gene construction and cloning**

VEGF_121 gene was amplified with specific primers which designed for specific sequence with restriction enzymes site at the tails (Figure 1A). The amplified PCR product and pET26b plasmid were digested, ligated and transformed into BL-21(DE3) E.coli competent cell. Some colonies were checked by Colony-PCR with T7 promoter and T7 terminator primers (Figure 1B), that all of them had the desired fragment. For further confirmation, NdeI and XhoI double digestion and sequencing was done (data not shown).

**Expression and purification of recombinant VEGF_121**

The recombinant protein was induced with different concentration of IPTG and the best expression was investigated in concentration of 1mM at 37°C for 12-14 hours. Expression was confirmed by SDS-PAGE and Western-Blotting (Figure 2). The recombinant VEGF_121 was expressed as His-tag fusion protein and purified with nickel affinity chromatography (Figure 2C). The yield of expression was detected by Bradford test and was evaluated about 5mg/liter.

**Proliferation assay**

As shown in Figure 3, the effect of recombinant VEGF_121 on HUVECs proliferation was dose dependent. We showed that increasing the concentration of VEGF_121 cause the increasing trend in HUVECs proliferation. However the increasing trend had a plateau at 75ng/ml of VEGF_121. According to the obtained results the concentration of 75ng/ml was used for further investigations. However with standard VEGF_121, the graph was reached plateau at concentration of 50ng/ml, and in comparison with our recombinant VEGF_121 its effect is moderately higher than recombinant VEGF_121 on HUVECs proliferation.

**Discussion**

Angiogenesis is a critical multi step process that resulted in the growth and sprouting solid tumor cells. It has been proved that inhibition of angiogenesis, is an effective way for treatment of solid tumors. Inhibition of angiogenesis is based on the blocking of new blood vessels formation through inhibition of interaction
between vascular growth factors and endothelial cells in tumor tissue.\textsuperscript{23} The most important vascular growth factor is VEGF, that is specific mitogen of endothelial cells and resulted in metastasis.\textsuperscript{23} Interaction of VEGF and its receptors (VEGFR-1 and VEGFR-2) is very important for tumor angiogenesis.\textsuperscript{23} So inhibition of VEGF and blocking of its signaling through interaction by its receptors could be promising tool for treatment of cancer.\textsuperscript{24} Given the importance of VEGF in angiogenesis in pathologic condition, and the widespread use of therapeutic factors in control of tumor progression, the main aim of this work was optimization of VEGF\textsubscript{121} expression in \textit{E.coli} and applying it as endothelial cell growth factor to studying angiogenesis \textit{in vitro}. According the importance of angiogenesis in the progression of some diseases, including cancer, Rheumatoid arthritis, diabetic retinopathy,\textsuperscript{11} recombinant production of this factor seems necessary which can induce angiogenesis for studying \textit{in vitro}. Right regulation of angiogenesis is related with right balance between inhibitors and inducers of it. For more than a decade, the role of VEGF in the regulation of angiogenesis has been studied. Some studies have focused on expression of VEGF;\textsuperscript{25-26} whereas in most of them, have been focused on the angiogenesis effect of VEGF\textsubscript{165}. For the first time in Iran, the roll of VEGF\textsubscript{121} on endothelial cell tube formation and angiogenesis were investigated.

![Figure 3. Proliferation effect of recombinant and standard commercial VEGF\textsubscript{121} on HUVEC cells. Different concentrations of VEGF\textsubscript{121} (10, 50, 75 and 100 ng/ml) was performed on HUVECs. With increasing the concentration of VEGF\textsubscript{121}, the increasing trend was observed in HUVEC proliferation which reached a plateau at 75ng/ml of VEGF\textsubscript{121} concentration (indicated by *). This effect is due to saturation of VEGF receptor on HUVECs. But, in case of standard VEGF\textsubscript{121} was used, the graph in concentration of 50ng/ml was reached to plateau. The assay was performed in triplicate and error bar represent for standard deviation. (mean±SD)](image)

![Figure 4. Effect of VEGF\textsubscript{121} on endothelial tube formation. The assay was followed at 4, 6 and 16 h after treatment with VEGF\textsubscript{121}. The tube formation was visualized through invert microscope (×10). As it can be seen the area of formed tubules increased by increasing time of HUVECs exposure with VEGF\textsubscript{121} and after 16 h exposure of HUVECs with VEGF\textsubscript{121} network formation was completed. The assay repeated four times.](image)
Recombinant Expression of human VEGF-A

Endothelial cell tube formation assay on matrix is as a first screen assay and has many advantages such as; rapidness, quantitative and can be done in high throughput level. Also it include all steps of angiogenic process; adhesion, migration, alignment and tube formation. Therefore this assay has many advantages over other assays such as migration, cell attachment, proliferation and invasion, which measure fewer steps in angiogenesis. However, this assay was first described over 20 years ago, but until to date this powerful assay has been widely used for identifying many various angiogenic and anti-angiogenic factors. Optimal result depends on some important conditions, like the number of coated cells. The optimal number of the cells is about 10000-15000 cells/well on 96-well plate. In case of primary cells, to obtain ideal tube formation, the cells must be in early passage (passage 2-6). Moreover the amount of matrix is important too and the best result of tube formation is observed in 50µl/well of 96-well plate. 

Our experiment showed that His-tagged VEGF121 was successfully expressed by E.coli BI-21(DE3). The total expression of the VEGF121 was 5mg per liter of culture. All isoforms of VEGF are glycosylated at Asn74, which is not affecting the VEGF biological activity. So the BL-21(DE3) is an appropriate host for our aim. According to results, VEGF121 resulted HUVECs proliferation in dose dependent manner. With increasing the concentration of VEGF121 no significant increasing in HUVECs proliferation was observed at dose higher than 75ng/ml. This phenomena may be indicated the saturation of VEGF receptors. Comparing the result of the recombinant VEGF121 with standard commercial VEGF121 showed that the effect of standard VEGF121 is moderately higher than our purified on HUVECs proliferation. We also showed that VEGF121 can induce endothelial tube formation and angiogenesis in vitro, in fact VEGF121 play an important role in angiogenesis process and endothelial cell tube formation. So this factor suggests the potential for novel therapeutic approaches.

Conclusion

According above mentioned and importance of angiogenesis in research to identify angiogenic and anti-angiogenic factor for treatment of different disease such as cancer, methods that inhibit angiogenesis are a promising rout for the treatment of angiogenesis-dependent disease. The purified VEGF121 was biologically active as assessed by proliferation of HUVECs and in vitro tube formation. The condition of expression that is explained in this study is expected to be applicable for large-scale production of various VEGF proteins in E.coli. Furthermore, VEGF121 can be used for research and clinical application in cancer researches.

Acknowledgments

This work was financially supported by Pasteur Institute of Iran, Tehran, Iran and Iran National Science Foundation (Grant No. 91004026).

Conflict of Interest

The authors declare that they have no conflict of interest.

References

16. Rahbarizadeh F, Ahmadvand D, Sharifzadeh Z. Nanobody; an old concept and new vehicle for


